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INTRODUCTION
The skin is a multilayered organ that exists in the
outermost region of the body against the environ-
ments, and the outermost layer of the skin is the
epidermis. In the epidermis, almost cells consist of
epidermal keratinocytes, and some melanocytes
scatter in the basal layer of the epidermis.
In this review, we focus on common skin tumors,
including benign, seborrheic keratosis (SK), and
malignant, squamous cell carcinoma (SCC) origi-
nated from keratinocytes, and malignant, melanoma
originated from melanocytes. We describe updates
on the molecular tumorigenesis of these tumors.
1. BENIGN SKIN TUMORS
seborrheic keratosis (SK)
SK is the most common benign skin tumor in
the whole body, and more common in areas of sun
exposure, especially the face. According to results of
transgenic mice, activation of fibroblast growth fac-
tor receptor (FGFR) 3 has been found to be relevant
to the pathogenesis of SK (1). FGFR3 belongs to
the FGFR family of transmembrane tyrosine kinase
receptors, and binding of ligands to FGFR3 stimu-
lates cell proliferation signals (2). The activation of
FGFR3 through somatic point mutations has been
identified in several kinds of cancer, e.g., bladder
carcinoma, multiple myeloma, and cervical cancer
(2). Transgenic mice with the expression of acti-
vated FGFR3 in the skin were reported in 2005
(1). They targeted FGFR3S249C (an activated mutant
FGFR3) to the basal cells of the epidermis of trans-
genic mice. At the age of 3-4 months, the transgenic
mice presented skin verrucous tumors on the eye-
lids and the snout, which showed similar histologi-
cal features to human SK. In addition, they screened
a series of 62 cases of SK for FGFR3mutations,
and 24 cases of these tumors (39%) harbored so-
matic activated FGFR3 mutations (1). We also ex-
amined mutations of FGFR3 gene in the Japanese
cases of SK, and activated FGFR3 mutations were
detected in 4 of 22 cases (18%) of SK (3). These
activated mutations were same as those mutations
found in cancers from the other organs in above.
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We examined FGFR3 protein expression by im-
munostainings because the above mutation rate in
our cases was not high. Twenty-seven of 31 cases
(87%) of SK showed moderately to strongly positive
expression of FGFR3 protein, but almost cases of the
other skin tumors, e.g., actinic keratosis, Bowen’s
disease, basal cell carcinoma, and SCC, were nega-
tive (3). Activation of FGFR3 might be a common
feature on the tumorigenesis of SK regardless of the
presence of the activated FGFR3 mutations. Since
activated FGFR3 mutations were detected in flat
lesions of SK and solar lentigo, activation of FGFR3
would be an early event on the development of SK
(4, 5).
The transcriptional factor forkhead box N1
(FOXN1) has been identified as a downstream tar-
get of FGFR3 (6). Activation of FGFR3 induces the
transcription of FOXN1, and FOXN1 also induces
the transcription of FGFR3, indicating a positive
feedback loop between FGFR3 and FOXN1 (6). The
positive FGFR3/FOXN1 feedback loop in SK was
confirmed by our analyses that all 11 cases of SK
showed moderately to strongly positive expression
of FOXN1 protein (7). FOXN1 might be also com-
monly activated in SK.
We have ever experienced a rare case of SCC de-
veloped in the lesion of SK. A 76-year-old female
had a black plaque in her leg for over 30 years, and
a red papule has developed in the lesion since 4
months (Fig. 1). The histological features showed
spindle cell SCC in the lesion of SK (Fig. 2). Since
the obvious expression of FGFR3 protein was ob-
served in not spindle cell SCC but SK by immuno-
stainings (Fig. 3), we supposed that down-regula-
tion of FGFR3 expression might be associated with
the development of spindle cell SCC in the lesion
of SK.
2. MALIGNANT SKIN TUMORS
It is widely accepted that normal keratinocytes or
melanocytes in the epidermis can convert to SCC or
melanoma, respectively, through the multistep proc-
ess that involves activation of oncogenes and/or
inactivation of tumor suppressor genes, similar to
malignant tumors originated from the other organs.
According to recent approaches by means of next-
generation sequencing in SCC (8) and melanoma
(9, 10), genomic DNA from tumor cells in a tumor
was prove to be not homogeneous. Many mutations
have been detected in genomic DNA from tumor
cells in a tumor with a variety of mutant allele fre-
quencies per each gene. A malignant tumor must be
basically monoclonal, however, “intratumor hetero-
geneity” is commonly found in each of malignant tu-
mors. Therefore, models of “clonal evolution (Fig.
4) (11)” and “trunk and branch (Fig. 5) (12)” have
been proposed as a model representative of the de-
velopment through the multistep process and a mod-
el representative of intratumor heterogeneity on theFig. 1 Clinical features.
Fig. 3 Immunohistochemical stainings for FGFR3.
Fig. 2 Histological features.
Y. Kubo, et al. Tumorigenesis of the Skin8
tumorigenesis of malignant tumors, respectively.
1) squamous cell carcinoma (SCC)
SCC is one of the most common skin cancers as-
sociated with a substantial risk of metastasis (13).
Exposure to the ultra-violet (UV), especially UVB,
radiation is the most common cause of SCC in sun-
light-exposed areas. If keratinocytes would fail to
have DNA damages due to UVB repaired, the ab-
normalities of genes would remain in them. Hyper-
carcinogenic states for SCC, where keratinocytes
are susceptible to the occurrence and accumulation
of gene mutations, consist of the inherited lesions,
e.g., xeroderma pigmentosum that is defective in
DNA base excision repair, and the acquired lesions,
e.g., chronic ulcers, burn and posttraumatic scars.
In addition, SCC occurs with high frequency in renal
allograft recipients after prolonged immunosuppres-
sion, probably due to Human papillomavirus (HPV)
infections, especially oncogenic types of HPV 16 and
18.
A novel approach by means of next-generation
sequencing in SCC has been reported by a group
of U.S.A. in 2011 (8). They performed exome-level
sequencing of 8 cases of primary SCC and matched
normal tissues, and detected a very large mutation
burden of approximately 1,300 somatic single-nucle-
otide variants per SCC exome (1 per30,000 bp of
coding sequence) (8). CT transition base substi-
tutions at dipyrimidine sites were the most com-
mon changes (85%), consistent with UV damage.
Among 1,300 somatic mutations, almost all muta-
tions would be “passenger” mutations (i.e., muta-
tions that never conferred a fitness advantage), and
some limited numbered mutations would be “driv-
er” mutations (i.e., mutations that confer or at some
point conferred a fitness advantage to the tumor
cell). Although whether a mutation is a real driver
mutation or not needs functional analyses with kera-
tinocytes and/or model animals, they selected some
candidates for driver genes based on many previous
results as shown in Table 1 (8). Among them, we
focus on well-known TP53 , CDKN2A , and HRAS
genes, and NOTCH genes as candidates for novel
driver genes.
Inactivated mutations of TP53 gene have been
found in approximately half cases of SCC as well as
various other human cancers (13-15). Allelic loss
on 17p, where TP53 gene locates, has been also ob-
served in approximately from 20 to 40% of cases of
SCC (16). As known as “guardian of the genome
(17)”, the cells that TP53 functions are lost would
render resistant for cell growth arrest and apoptosis,
and would be susceptible to the occurrence and ac-
cumulation of gene mutations in addition to accel-
erated cell growth. Because inactivated mutations
of TP53 gene have been found in lesions of solar
keratosis and apparently histological normal skin,
the mutations might occur at the early stage in the
development of SCC (14). Seven of 8 cases of SCC
also showed inactivation of both alleles of TP53 gene
as shown in Table 1 (8).
Similar to TP53 gene, seven of 8 cases of SCC also
Fig. 4 Evolution of cancer cells.
Fig. 5 Trunk and branch model. Common or ubiquitous events
in the tumor found in every subclone and every tumor region are
represented in the trunk of the tree. Diverse, heterogeneous so-
matic events are represented by the branches and the leaves.
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showed inactivation of NOTCH genes as shown in
Table 1 (8). Allelic loss on 9q, where NOTCH1 gene
locates, has been also observed in approximately
from 20 to 40% of cases of SCC (16). NOTCH1 mu-
tations were detected in 9 of 11 cases of SCC (18),
including 8 cases of SCC in Table 1 (8), and loss of
normal allele of NOTCH1 gene was found in 3 of 9
cases of SCC with inactivated NOTCH1 mutations
(18). Inactivated NOTCH2 , NOTCH3 , and NOTCH4
mutations were detected in 5, 3, and 3 of 11 cases of
SCC (18), including 8 cases of SCC in Table 1 (8),
respectively. Since NOTCH has been reported to be
a negative regulator of keratinocyte stem cell po-
tential and inducer of differentiation (19), NOTCH
genes must be novel driver genes.
CDKN2A gene encodes two different tumor sup-
pressor gene products, p16INK4a and p14ARF (20).
p16INK4a is involved in the function of cell growth sup-
pression of RB1 by binding cyclin dependent kinase
4/6 (CDK4/6) and inhibiting their enzyme activi-
ties, and p14ARF is involved in the function of cell
growth arrest and apoptosis of TP53 by binding
MDM2 and stabilizing TP53. Since mutations of
CDKN2A gene have been detected mainly in a com-
mon exon to both p16INK4a and p14ARF, their mutations
would inactivate both of RB1 and TP53. Mutations
of CDKN2A gene have been reported in up to 20% of
SCCs (13), and allelic loss on 9p, where CDKN2A
gene locates, has been also observed in approxi-
mately from 20 to 40% of cases of SCC (16). In ad-
dition, epigenetic abnormalities by promoter hyper-
methylation have been found in 35% of cases of SCC
(21). Two of 8 cases of SCC also showed inactivation
of both alleles of CDKN2A gene as shown in Table
1 (8).
HRAS is one of three RAS genes, including HRAS ,
KRAS , and NRAS , and activated RAS mutations are
one of the most common genetic abnormalities in
various human cancers (22). The RAS proteins are
small G-proteins, and transduce intracellular signals,
especially mitogen-activated protein kinase (MAPK)
cascades (RAS-RAF-MEK-ERK) and phosphatidy-
linositol-3 kinase (PI3K) cascades. Activated RAS
mutations produce many tumor-promoting effects,
e.g., accelerating cell growth, inhibiting apoptosis,
through the activated downstream cascades. Acti-
vated HRAS mutations have not been frequently de-
tected in cases of SCC. The rate of HRAS muta-
tions was 5% in our cases of SCC (13), and one of 8
cases of SCC also showed an activated HRAS mu-
tation as shown in Table 1 (8).
We have already performed functional analyses
by transducing candidate driver genes in normal
human keratinocytes (23, 24). Using high efficiency
retroviral transductions in normal human primary
keratinocytes, we expressed HRASV12 (an activated
mutant HRAS), CDK4, TP53W248 (a dominant-nega-
tive mutant TP53), and TERT either singly or in
combination, and used these cells to regenerate hu-
man skin on SCID mice (23). Among them, a com-
bination of HRASV12 and CDK4 produced human
skin tumors with histologic features of SCC at 6
weeks after grafting (23), indicating that HRASV12
and CDK4 must be driver genes as capable of con-
verting normal human epidermal tissue into invasive
neoplasia. Tumor accelerating effects by HRASV12
Table 1. Cases and selected mutations described in Table 1 (Ref. 8)
Sex Age Site Immunestatus TP53 CDKN2A NOTCH1 NOTCH2 NOTCH3 NOTCH4
Other known
COSMIC
mutations
1 M 76 Scalp + R248W P135L Q610X W330X,R1838X EP300, WT1
2 M 87 Scalp + E285K P1771S,R1595Q P226S WT1
3 M 84 Left dorsalhand +
E224
(Splice site) C478F R1333C
4 F 61 Left cheek + Y220N W309X PIK3CG
5 M 83 Left cheek + H179Y,P278S W1769X
Q1634X,
T2278I S1602F
6 M 85 Right temple + P142N,H179Y P133L (Splice site)
S1836F,
E297K EZH2
7 M 58 Left auralhelix -
E286K,
T329I, E349X Q1924X
Q1616X,
G488D HRAS
8 M 63 Lower lip + HSPB2
Boldface denotes loss of wild- type allele.
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and CDK4 were summarized in Fig. 6. We believe
that a combination of activation of RAS and inactiva-
tion of RB1/p16INK4a might be crucial to the carcino-
genesis at least in a subset of cases of SCC, because
we actually found a case of SCC with both an acti-
vated HRAS mutations and an inactivated CDKN2A
mutation (Fig. 7) (13). In addition, the combination
of HRASV12 and CDK4 produced invasive three-di-
mensional organotypic neoplasia from normal hu-
man epithelia from not only the skin, but also oro-
pharynx, esophagus and cervix (25). Thus, the com-
bination should be a common model of human SCC
from the skin and the other organs.
2) melanoma
melanoma is known to be the most aggressive
malignant skin tumor. Most cases of melanoma in
Japan show black because of tumors with large a-
mounts of melanin. Much more reports about mo-
lecular tumorigenesis of melanoma have been accu-
mulated so far, and several diver genes in melanoma
have been already identified (26). We summarize
diver genes in melanoma in Fig. 8. Activation of
NRAS BRAF , and KIT genes was often observed as
oncogenes, and CDKN2A , PTEN , and TP53 genes
were often inactivated as tumor suppressor genes
(26). Both MAPK cascades and PI3 kinase cascades
were activated through activation of NRAS gene, and
MAPK cascades or PI3 kinase cascades were acti-
vated through activation of BRAF gene or inactiva-
tion of PTEN gene, respectively.
In terms of differences of the molecular tumori-
genesis, melanoma was divided into 4 groups, in-
cluding melanoma on skin without chromic sun-in-
duced damage (non-CSD), melanoma on skin with
chromic sun-induced damage (CSD), acral melano-
ma, and mucosal melanoma in 2006 (Fig. 9) (27).
Acral melanoma is the most popular in Japan. As
shown in Fig. 9, activated BRAF mutations were the
most frequently observed, and activated NRAS mu-
tations were relatively frequently observed in non-
CSD melanoma. However, activated KIT mutations
were relatively frequently observed in other 3 groups
of melanoma. Among 3 groups of melanoma except
for non-CSD melanoma, the frequencies of activated
mutations of BRAF gene or NRAS gene varied.
Several approaches by means of next-generation
sequencing have been already performed in mela-
noma (9, 10, 28). Activation of oncogenes and inacti-
vation of tumor suppressor genes described in above
have been confirmed, and some novel driver genes
have been identified on the tumorigenesis of mela-
noma. Among them, some groups noticed RAC1 as
one of molecules associated with MAPK cascades
(9, 10). Recurrent somatic activated RAC1 muta-
tions, inducing activation of MAPK cascades, were
found in approximately 5% cases of melanoma. In
addition to RAC1, many molecules associated with
MAPK cascades were found to be activated in a sub-
set of melanoma. Activation of MAPK cascades by
activation of molecules, including BRAF, NRAS, and
RAC1, was commonly observed in melanoma.
Same efforts as SCC for making human melano-
ma models have been performed in Stanford Uni-
versity (29). Similar to human SCC models, using
high efficiency retroviral transductions in normal
human primary melanocytes, they expressed can-
didate driver genes either singly or in combination,
and used these cells with normal human keratino-
cytes to regenerate human skin on SCID mice. Hu-
man skin tumors with histologic features of melano-
ma were produced by three types of combinations of
drivers : NRASG12V, CDK4R24C, and TERT ; NRASG12V,
TP53R248W, and TERT ; PI3K p110α, CDK4R24C,
Fig. 6 Tumor accelerating effects by HRASV12 and CDK4.
Fig. 7 Clinical features. A reddish large tumor is seen in the pa-
rietal region of her head.
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TP53R248W, and TERT (29). In contrast to human SCC
models, TERT as a reverse transcriptase of telome-
rase was essential for human melanoma models.
Recently, activation of TERT has been reported in
human melanoma (30, 31). Recurrent TERT promot-
er mutations were observed in 50 of 70 (71%) cases
of melanoma, and the mutation increased transcrip-
tional activities from the TERT promoter by 2 to 4-
fold (30). Activation of TERT was commonly ob-
served in melanoma (30, 31). These results were
consistent with human melanoma models in above.
In addition to novel immunotherapies with anti-
CTLA4 antibody and/or anti-PD-1 antibody, novel
therapies based on the tumorigenesis of melanoma
have been tried for advanced melanoma (26, 32).
Imatinib as an inhibitory drug to target KIT showed
effective for a subset of melanoma with activated
KIT mutations (33). Some inhibitory drugs to target
BRAF or MEK showed effective for a subset of mel-
anoma with activated BRAF mutations, and com-
bination therapies of dual inhibition of BRAF and
MEK showed more effective, although combination
therapies were very expensive (32, 34). On the oth-
er hand, combination therapies of dual inhibition of
MEK and CDK4 showed effective for a subset of
melanoma with activated NRAS mutations (35). We
believe that combination therapies of dual inhibition
of MEK and CDK4 might be also effective for cases
of SCC with activated HRAS mutations as shown in
Fig. 6.
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CONCLUDING REMARKS
SCC and melanoma sometimes recur or metasta-
size after surgical excision. Advanced SCC and mel-
anoma are often resistant for radiation treatment
and chemotherapy. We hope that the molecular tu-
morigenesis of SCC and melanoma would be eluci-
dated in detail to establish novel effective therapies
for advanced SCC and melanoma based on their
own molecular tumorigenesis.
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